Rectal cancer combo trial pulled before starting
NCT ID NCT07223567
First seen Nov 03, 2025 · Last updated May 21, 2026 · Updated 25 times
Summary
This study was designed to test a combination of two drugs, regorafenib and lorigerlimab, in people with a certain type of rectal cancer that came back after initial treatment. The goal was to see if the combination was safe and effective. However, the study was withdrawn before any participants were enrolled.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for RECTAL CANCER are added.
Genom att skicka in godkänner du våra Användarvillkor
Conditions
Explore the condition pages connected to this study.